Dr Zamagni speaks to ecancer about a recent study presented at ASH 2020 regarding the impact of imaging FDG-PET/CT minimal residual disease assessment on outcomes and complementarity with multiparameter flow cytometry in newly diagnosed transplant eligible multiple myeloma (MM) patients enrolled in the phase II randomised FORTE trial.
She says that 18F-FDG-PET/CT is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in multiple myeloma (MM) patients. Whilst explaining the objective of this analysis she says that in this analysis, we aimed at comparing MRD data by PET/TC assessment and MFC in the multicentre phase II randomised FORTE trial for NDTEMM patients. She the explains the methodology used in this study and highlights some of the key results obtained from this study.
In conclusion, Dr Zamagni says that the present analysis confirms the applicability and validity of DS criteria for the definition of PET/CT MRD outside the BM in an independent prospective series of NDTEMM patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.